Beyond Drug Delivery: Three Lenses For Selecting An On-Body Platform

As biologics continue to shift toward large-volume subcutaneous delivery, selecting an on-body platform has become a strategic decision that extends well beyond basic drug administration. In this discussion, Reto Jost, Nadine Kaufmann and Shawn James explore three complementary lenses for evaluating wearable delivery solutions: technical and therapeutic fit, usability and program readiness, and end-of-life performance.

The conversation examines how factors such as volume, viscosity, human factors engineering, manufacturing maturity, and regulatory readiness can influence development timelines, patient confidence, and commercial success. It also highlights the growing importance of lifecycle thinking, including approaches to reducing drug waste, supporting recycling, and improving resource efficiency.

For pharmaceutical companies developing next-generation biologics, these insights provide a practical framework for making early platform decisions that can create value across the entire product lifecycle.